A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Effectiveness of TRS005 in Patients With Relapsed or Refractory CD20-positive NHL.

  • participants needed
  • sponsor
    Zhejiang Teruisi Pharmaceutical Inc.
Updated on 3 December 2022


This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.


The subjects were screened and examined according to the protocol before enrollment。The dose of the enrolled subjects was increased according to the following 7 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, 2.0mg/kg and 2.3 mg/kg. (according to the data of the previous study, when the dose climbs to 1.5 mg / kg, there is a serious decline of neutrophils, which shall be subject to the principle of 3 + 3. If the dose group reaches 6 patients and the DLT is less than or equal to 1 case, it continues to increase sequentially (1.8 mg/kg, 2.0 mg/kg, and 2.3 mg/kg). Whether to continue the dose increase or not shall be discussed and decided by the researcher and the sponsor). The incremental process is divided into groups according to the principle of 3 + 3 dose increment. The subjects randomly receive intravenous drip of TRS005 in chronological order. Each subject first carries out a single dose study, and then carries out multiple continuous doses. The first dose is given once in D1. After 21 days of observation, it is decided whether to continue multiple continuous doses according to the situation. They are given once in C2D1, C3D1, C4D1, C5D1 and C6D1 respectively, for a total of 6 cycles and 6 times.

Based on the data of pharmacokinetics, safety, tolerability and efficacy of the previous 4 dose groups, the dose group of 1.0 mg/kg, 1.5 mg/kg or 1.8 mg/kg (when the maximum dose exceeds 1.8 mg/kg) will enter the extended trial phase and continue to complete 6 cycles of treatment according to the original research principles. It is expected that the number of research cases in each group will accumulate to 10, a total of about 30 cases; If 2 cases of DLT occur in 6 cases in the 1.5 mg/kg dose group, the dose increase will not continue. At this point, an additional 1.3 mg/kg dose group is required to enter the study, while the extended dose group is expected to select 1.0 mg/kg 1.3 mg/kg, with a cumulative enrollment of 12 subjects, for a total of 24 cases.

Condition CD20-positive B-cell Non-Hodgkin Lymphoma
Treatment Recombinant anti-CD20 monoclonal antibody-MMAE coupling agent for injection (TRS005)
Clinical Study IdentifierNCT05395533
SponsorZhejiang Teruisi Pharmaceutical Inc.
Last Modified on3 December 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note